mir-3180 microRNA precursor family
| mir-3180 | |
|---|---|
 Conserved secondary structure of the mir-3180 miRNA. | |
| Identifiers | |
| Symbol | mir-3180 |
| Rfam | RF02010 |
| miRBase family | MIPF0000894 |
| HGNC | 38382 |
| Other data | |
| RNA type | microRNA |
| Domain(s) | Eukaryota; Metazoa |
| PDB structures | PDBe |
In molecular biology mir-3180 microRNA is a short RNA molecule. MicroRNAs function to regulate the expression levels of other genes by several mechanisms.[1] The mir-10 microRNA precursor is a short non-coding RNA gene that is part of an RNA gene family which contains mir-3180-1, mir-3180-2, mir-3180-3, mir-3180-4 and mir-3180-5. They have now been predicted or experimentally confirmed in a wide range of cancers in humans.[2][3] (MIPF0000894, mir-3180) mir-3180 has currently only been identified in human Homo sapiens.
Species distribution[edit]
The presence of mir-3180 has been detected in a range of catarrhine monkeys. It has been identified in primates including human (Homo sapiens), Sumatran orangutan (Pongo abelii), western lowland gorilla (Gorilla gorilla gorilla), Northern white-cheeked gibbon (Nomascus leucogenys), Chlorocebus sabaeus (Chlorocebus sabaeus), Olive baboon (Papio anubis) and Rhesus monkey (Macaca mulatta).[4][5] In some of these species the presence of mir-3180 has been shown experimentally, in others the genes encoding mir-3180 might have been predicted computationally.
Genomic location[edit]
The mir-3180 genes are found within the Chromosome 16. In humans there are five mir-3180 clusters, these contain five genes encoding miRNAs (mir-3180-1, mir-3180-2, mir-3180-3, mir-3180-4 and mir-3180-5). The mir-3180 genes have the following locations:
hsa-mir-3180-1 chr16 Start: 14911220 End: 14911313 Strand: +
hsa-mir-3180-2 chr16 Start: 16309879 End: 16309966 Strand: +
hsa-mir-3180-3 chr16 Start: 18402178 End: 18402271 Strand: -
hsa-mir-3180-4 chr16 Start: 15154850 End: 15155002 Strand: -
hsa-mir-3180-5 chr16 Start: 2135977 End: 2136129 Strand: -
Association with cancer[edit]
Recently there has been much interest in abnormal levels of expression of microRNAs in cancers. Upregulation of mir-3180 has been found in cancers. Increased levels of mir-3180 have been found in colon cancer.[6]
See also[edit]
Further reading[edit]
- ^ Qureshi A, Thakur N, Monga I, Thakur A, Kumar M (1 January 2014). "VIRmiRNA: a comprehensive resource for experimentally validated viral miRNAs and their targets". Database. 2014: bau103. doi:10.1093/database/bau103. PMC 4224276. PMID 25380780.
- ^ Jin L, Zhang Z (December 2020). "Serum miR-3180-3p and miR-124-3p may Function as Noninvasive Biomarkers of Cisplatin Resistance in Gastric Cancer". Clinical Laboratory. 66 (12). doi:10.7754/Clin.Lab.2020.200302. PMID 33337849.
- ^ Sayagués JM, Corchete LA, Gutiérrez ML, Sarasquete ME, Del Mar Abad M, Bengoechea O, et al. (November 2016). "Genomic characterization of liver metastases from colorectal cancer patients". Oncotarget. 7 (45): 72908–72922. doi:10.18632/oncotarget.12140. PMC 5341953. PMID 27662660.
- ^ Creighton CJ, Benham AL, Zhu H, Khan MF, Reid JG, Nagaraja AK, et al. (March 2010). "Discovery of novel microRNAs in female reproductive tract using next generation sequencing". PLOS ONE. 5 (3): e9637. Bibcode:2010PLoSO...5.9637C. doi:10.1371/journal.pone.0009637. PMC 2835764. PMID 20224791.
- ^ Stark MS, Tyagi S, Nancarrow DJ, Boyle GM, Cook AL, Whiteman DC, et al. (March 2010). "Characterization of the Melanoma miRNAome by Deep Sequencing". PLOS ONE. 5 (3): e9685. Bibcode:2010PLoSO...5.9685S. doi:10.1371/journal.pone.0009685. PMC 2837346. PMID 20300190.
- ^ Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T, Kure EH (2012). Cho WC (ed.). "Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing". PLOS ONE. 7 (4): e34150. Bibcode:2012PLoSO...734150H. doi:10.1371/journal.pone.0034150. PMC 3328481. PMID 22529906.
External links[edit]
 | This genetics article is a stub. You can help Wikipedia by expanding it. |